Russian Ministry of Health recommends Ilsira® for the treatment of COVID-19

14.09.2020

Russian Ministry of Health recommends Ilsira® for the treatment of COVID-19

On September 3, Ilsira®, our original drug for the treatment of severe complications in COVID-19 patients was included in the guidelines of the Ministry of Health of the Russian Federation. This will help ensure the massive use of drug therapy across Russian regions.

More Category: News
Hit Hard by Coronavirus, Russia Joins Global Race for a Vaccine

15.06.2020

Hit Hard by Coronavirus, Russia Joins Global Race for a Vaccine

When a vaccine is ultimately approved, Russian companies such as BIOCAD, a private biotech company based in St. Petersburg that is working with several vaccine developers, are expected to be at the forefront of manufacturing it.

More Category: Publication
New drug for melanoma treatment got approved

15.06.2020

New drug for melanoma treatment got approved

On April 20, the Russian Ministry of Health approved the first Russian original PD-1 inhibitor Forteca® (INN: prolgolimab) for the treatment of one of the most aggressive types of cancer—metastatic or inoperable melanoma. Prolgolimab acts as PD-1 inhibitor and helps to restore the ability of the human immune system to fight a tumor. Its registration was an important for the development of immuno-oncology and treatment of patients with malignant neoplasms.

More Category: News
BIOCAD has become an industrial partner of Vector in the development of a COVID-19 vaccine

15.06.2020

BIOCAD has become an industrial partner of Vector in the development of a COVID-19 vaccine

The biotechnology company BIOCAD has signed an agreement with the State Scientific Center for Virology and Biotechnology «Vektor» (Novosibirsk) on joint work on a vaccine based on rVSV against the COVID-19 virus. The vaccine development process has reached the final animal safety study stage. The cooperation agreement was signed by Dmitry Morozov (BIOCAD) and Rinat Maksyutov (Vector). According to the parties, the vaccine showed high promise in tests on laboratory animals, including lower primates.

More Category: News
11 clinical sites have joined the study of the Russian drug against COVID-19

15.06.2020

11 clinical sites have joined the study of the Russian drug against COVID-19

Initially, the drug was developed to treat rheumatoid arthritis. BIOCAD developers receive regulatory authorization as part of the procedure approved by Decree No. 441 of the Government of the Russian Federation of April 4, 2020 since the mechanism of action of the active substance is associated with the cytokine storm, a life-threatening immune system response in patients with COVID-19.

More Category: News